HEMATOLOGY LECTURE NOTES

Lymphocyte counts less than 0.75 x 109 cells/L were associated with an increased incidence of serious infections. It is not recommended to initiate or continue XELJANZ treatment in patients with a confirmed lymphocyte count less than 0.75 x 109 cells/L. Lymphocytes should be monitored at baseline and every 3 months thereafter. ................
................

In order to avoid copyright disputes, this page is only a partial summary.